## nature research

| Corresponding author(s):   | Peng Hou     |
|----------------------------|--------------|
| Last updated by author(s): | Oct 29, 2020 |

## **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

| _  |          |      |   |
|----|----------|------|---|
| C- | <br>Fic: | tico | • |
| _  | <br>     | 111  |   |

| For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.   |   |   |  |  |
|---|---|---|--|--|
| n/a   | Confirmed   |   |  |  |
|   | The exact   | sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement   |  |  |
|   | A stateme   | ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly   |  |  |
|   | The statist   | tical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.   |  |  |
| $\boxtimes$   | A descript  | ion of all covariates tested  |  |  |
| $\boxtimes$   | A descript  | ion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |  |  |
| $\boxtimes$   |   | cription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) tion (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |  |  |
| $\boxtimes$   | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i> |   |  |  |
| $\boxtimes$   | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |   |  |  |
| $\boxtimes$   | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |   |  |  |
| Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated  |   |   |  |  |
| Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.   |   |   |  |  |
| Software and code   |   |   |  |  |
| Policy information about <u>availability of computer code</u>   |   |   |  |  |
| Da  | ta collection   | No software was used.   |  |  |
| Da  | ta analysis   | SPSS 22 and GraphPad Prism 6.0 were used in this study.   |  |  |
| For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. |   |   |  |  |

## Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

| Field-specific reporting                    |  |  |  |  |
|---|--|--|--|--|
| Please select the or                        | be below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.  Behavioural & social sciences   |  |  |  |
| For a reference copy of t                   | ne document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>   |  |  |  |
| Life scier                                  | ces study design   |  |  |  |
| All studies must dis                        | close on these points even when the disclosure is negative.  |  |  |  |
| Sample size                                 | Disclosure is not applicable.  |  |  |  |
| Data exclusions                             | No data were excluded.   |  |  |  |
| Replication                                 | Each assay was repeated in triplicate, and the replication were successful.  |  |  |  |
| Randomization                               | Disclosure is not applicable.  |  |  |  |
| Blinding                                    | Investigators are blind during analysis.   |  |  |  |
|   |  |  |  |  |
| Reportin                                    | g for specific materials, systems and methods  |  |  |  |
|   | on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, ed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.   |  |  |  |
| Materials & exp                             | perimental systems Methods   |  |  |  |
| n/a Involved in th                          | e study n/a Involved in the study  |  |  |  |
| Antibodies                                  | ∑ ChIP-seq   |  |  |  |
| Eukaryotic                                  |  |  |  |  |
|   | ngy and archaeology MRI-based neuroimaging   |  |  |  |
|   | d other organisms  |  |  |  |
|   | Human research participants  |  |  |  |
| Clinical data  Dual use research of concern |  |  |  |  |
| Antibodies                                  |  |  |  |  |
| Antibodies used                             | All the antibodies used in this study are listed in supplementary Table 3.   |  |  |  |
| Validation                                  | All the antibodies are validated before use.   |  |  |  |
| validation                                  | All the altibodies are validated before use.   |  |  |  |
| Eukaryotic c                                | ell lines  |  |  |  |
| Policy information a                        | about <u>cell lines</u>  |  |  |  |
| Cell line source(s)                         | Human thyroid cancer cell lines 8305C and BCPAP were kindly provided by Dr. Haixia Guan (The First Affiliated Hospital of China Medical University, Shenyang, China). Human melanoma cell line A375, gastric cell line AGS, colon cancer cell line RKO and mouse MC38 and B16F10 cells were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Human breast cancer cell line MDA-MB-231 was obtained from Shanghai Cell Bank, Chinese Academy of Sciences (Shanghai, China). |  |  |  |
| Authentication                              | All cell lines were used authorized.   |  |  |  |

All the cell lines were tested negative for mycoplasma.

No such cell lines were used.

Mycoplasma contamination

Commonly misidentified lines (See <u>ICLAC</u> register)